ARCHIVES

Amgen Claimed QOL Benefit Despite FDA Label Change.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

Organ Systems Program Defenders Go On Offense At NCAB Committee Meeting

December 11, 1987

BCI Budget Chief Browning To Retire

January 12, 1979

NCI, FDA Are Feuding Again, This Time Overcharge That DCT Moved Too Slowly On Toxicity Notification

April 10, 1981

NCI Is Considering New Core Grants For Prostate, Breast Research Centers

April 19, 1991

Rauscher Tabs Oak Ridge Immunologists To Head Basic Research At Frederick

August 30, 1974

Wilding named director, Univ. of Wisconsin Cancer Center.

January 30, 2004